141 related articles for article (PubMed ID: 35652548)
1. PSA density is associated with BPH cellular composition.
Jia L; Strand DW; Goueli RS; Gahan JC; Roehrborn CG; Mauck RJ
Prostate; 2022 Sep; 82(12):1162-1169. PubMed ID: 35652548
[TBL] [Abstract][Full Text] [Related]
2. Risk Analysis of Prostate Cancer Development Following Five-alpha Reductase Inhibitor Treatment for Benign Prostate Hyperplasia.
Chang LW; Wang SS; Yang CK; Lu K; Chen CS; Cheng CL; Hung SC; Chiu KY; Hsu CY; Li JR
Anticancer Res; 2023 Jan; 43(1):485-491. PubMed ID: 36585197
[TBL] [Abstract][Full Text] [Related]
3. Transcriptomic analysis of benign prostatic hyperplasia identifies critical pathways in prostatic overgrowth and 5-alpha reductase inhibitor resistance.
Jin R; Forbes CM; Miller NL; Lafin J; Strand DW; Case T; Cates JM; Liu Q; Ramirez-Solano M; Mohler JL; Matusik RJ
Prostate; 2024 Apr; 84(5):441-459. PubMed ID: 38168866
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis.
Kim JH; Baek MJ; Sun HY; Lee B; Li S; Khandwala Y; Del Giudice F; Chung BI
PLoS One; 2018; 13(10):e0203479. PubMed ID: 30281615
[TBL] [Abstract][Full Text] [Related]
5. Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia.
Haese A; Graefen M; Noldus J; Hammerer P; Huland E; Huland H
J Urol; 1997 Dec; 158(6):2188-92. PubMed ID: 9366341
[TBL] [Abstract][Full Text] [Related]
6. Polygenic risk score predicting susceptibility and outcome of benign prostatic hyperplasia in the Han Chinese.
Hung SC; Chang LW; Hsiao TH; Lin GC; Wang SS; Li JR; Chen IC
Hum Genomics; 2024 May; 18(1):49. PubMed ID: 38778357
[TBL] [Abstract][Full Text] [Related]
7. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.
Roehrborn CG; Boyle P; Gould AL; Waldstreicher J
Urology; 1999 Mar; 53(3):581-9. PubMed ID: 10096388
[TBL] [Abstract][Full Text] [Related]
8. [5ARI and PSA: therapeutic aspects].
Sciarra A
Urologia; 2014 Sep; 81 Suppl 24():17-20. PubMed ID: 24744217
[TBL] [Abstract][Full Text] [Related]
9. 5-Alpha reductase inhibitors induce a prostate luminal to club cell transition in human benign prostatic hyperplasia.
Joseph DB; Henry GH; Malewska A; Reese JC; Mauck RJ; Gahan JC; Hutchinson RC; Mohler JL; Roehrborn CG; Strand DW
J Pathol; 2022 Apr; 256(4):427-441. PubMed ID: 34928497
[TBL] [Abstract][Full Text] [Related]
10. [5ARI and PSA: evidences].
Morgia G; Urzì D; Russo GI
Urologia; 2014 Sep; 81 Suppl 24():4-11. PubMed ID: 24803356
[TBL] [Abstract][Full Text] [Related]
11. Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis.
Morlock R; Goodwin B; Gomez Rey G; Eaddy M
Clin Ther; 2013 May; 35(5):624-33. PubMed ID: 23583026
[TBL] [Abstract][Full Text] [Related]
12. Glucocorticoids are induced while dihydrotestosterone levels are suppressed in 5-alpha reductase inhibitor treated human benign prostate hyperplasia patients.
Jin R; Forbes C; Miller NL; Strand D; Case T; Cates JM; Kim HH; Wages P; Porter NA; Mantione KM; Burke S; Mohler JL; Matusik RJ
Prostate; 2022 Oct; 82(14):1378-1388. PubMed ID: 35821619
[TBL] [Abstract][Full Text] [Related]
13. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
[TBL] [Abstract][Full Text] [Related]
14. Is one single prostate biopsy helpful for choosing a medical treatment of benign prostatic hyperplasia? A quantitative computerized morphometric study.
Zlota Ar; Sattar AA; Wespes E; Noel JC; Schulman CC
Urology; 1996 Mar; 47(3):329-34. PubMed ID: 8633397
[TBL] [Abstract][Full Text] [Related]
15. Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
Haese A; Graefen M; Steuber T; Becker C; Noldus J; Erbersdobler A; Huland E; Huland H; Lilja H
J Urol; 2003 Dec; 170(6 Pt 1):2269-73. PubMed ID: 14634394
[TBL] [Abstract][Full Text] [Related]
16. 5α-Reductase inhibitor is less effective in men with small prostate volume and low serum prostatic specific antigen level.
Lin VC; Liao CH; Wang CC; Kuo HC
J Formos Med Assoc; 2015 Sep; 114(9):865-71. PubMed ID: 24064231
[TBL] [Abstract][Full Text] [Related]
17. Five-alpha reductase inhibitor influences expression of androgen receptor and HOXB13 in human hyperplastic prostate tissue.
Jung C; Park Y; Kim YR; Ryu SB; Kang TW
Int Braz J Urol; 2013; 39(6):875-83. PubMed ID: 24456780
[TBL] [Abstract][Full Text] [Related]
18. Role of the transition zone for elevating serum prostate-specific antigen in benign prostatic hyperplasia.
Sakamoto W; Iwata H; Kamikawa S; Tsurusaki K; Sugimoto T; Nakatani T; Sugimura K; Yamamoto K; Kishimoto T
Int J Urol; 1998 Mar; 5(2):163-6. PubMed ID: 9559843
[TBL] [Abstract][Full Text] [Related]
19. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
[TBL] [Abstract][Full Text] [Related]
20. Relationship between changes in prostate-specific antigen and the percent of prostatic epithelium in men with benign prostatic hyperplasia.
Cadeddu JA; Pearson JD; Lee BR; Landis P; Partin AW; Epstein JI; Carter HB
Urology; 1995 May; 45(5):795-800. PubMed ID: 7538241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
